Daiichi Sankyo looking to sell OTC drug unit for about $900 million: Nikkei Business [Reuters]
JP Morgan Chase & Co. (JPM)
Last jp morgan chase & co. earnings: 4/14 06:43 am
Check Earnings Report
US:NYSE Investor Relations:
jpmorganchase.com/corporate/investor-relations/investor-relations.htm
Company Research
Source: Reuters
Daiichi Sankyo looking to sell OTC drug unit for about $900 million: Nikkei Business - Reuters 1 Min Read TOKYO (Reuters) - Japan’s Daiichi Sankyo Co is in talks with several companies to sell its wholly owned over-the-counter (OTC) drug unit, with the final price likely to reach around 100 billion yen ($900 million), Nikkei Business reported on Thursday. Reuters reported earlier this year that Japan’s No. 4 drugmaker had hired JPMorgan to advise on the potential sale of the unit, Daiichi Sankyo Healthcare. A Daichi Sankyo spokesman declined to comment on the Nikkei Business report. Daiichi Sankyo is focusing on developing cancer treatments to offset a revenue drop following patent expirations of its mainstay blood pressure drug. The OTC unit makes an energy drink, Regain, as well as the Lulu Attack cold medicine and Gaster 10 stomach medicine. Reporting by Takashi Umekawa and Chang-Ran Kim; Editing by Stephen Coates All quotes delayed a minimum of 15 minutes. See here for a complet
Show less
Read more
Impact Snapshot
Event Time:
JPM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
JPM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
JPM alerts
High impacting JP Morgan Chase & Co. news events
Weekly update
A roundup of the hottest topics
JPM
News
- Jamie Dimon says to get a job at JPMorgan, what you study in college ‘almost doesn't matter' [Fortune]Fortune
- Why it may be time to start looking at value stocks [Yahoo! Finance]Yahoo! Finance
- UBS Weighs Synthetic Risk Transfer Amid Capital Boost Proposals [Yahoo! Finance]Yahoo! Finance
- UBS Weighs Synthetic Risk Transfer Amid Capital Boost Proposals [BNN Bloomberg (Canada)]BNN Bloomberg
- Wall St Week Ahead Lofty US stocks leave investors punishing earnings disappointments [Reuters]Reuters
JPM
Earnings
- 4/12/24 - Beat
JPM
Sec Filings
- 4/26/24 - Form 424B2
- 4/26/24 - Form 424B2
- 4/26/24 - Form 424B2
- JPM's page on the SEC website